Nebula Genomics, the startup that wants to put your whole genome on the blockchain, has announced the raise of $4.3 million in Series A from Khosla Ventures and other leading tech VC’s such as Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs.
Nebula has also has forged a partnership with genome sequencing company Veritas Genetics .
Veritas was one of the first companies to sequence the entire human genome for less than $1,000 in 2015, later adding all that info to the touch of a button on your smartphone. Both Nebula and Veritas were cofounded by MIT professor and “godfather” of the Human Genome Project, George Church.
The partnership between the two companies will allow the Nebula marketplace, or the place where those consenting to share their genetic data can earn Nebula’s cryptocurrency called “Nebula tokens” to build upon Veritas open-source software platform Arvados, which can process and share large amounts of genetic information and other big data. According to the company, this crossover offers privacy and security for the physical storage and management of various data sets according to local rules and regulations.
“As our own database grows to many petabytes, together with the Nebula team we are taking the lead in our industry to protect the privacy of consumers while enabling them to participate in research and benefit from the blockchain-based marketplace Nebula is building,” Veritas CEO Mirza Cifric said in a statement.
The partnership will work with various academic institutions and industry researchers to provide genomic data from individual consumers looking to cash in by sharing their own data, rather than by freely giving it as they might through another genomics company like 23andMe .
“Compared to centralized databases, Nebula’s decentralized and federated architecture will help address privacy concerns and incentivize data sharing,” added Nebula Genomics co-founder Dennis Grishin. “Our goal is to create a data flow that will accelerate medical research and catalyze a transformation of health care.”